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Health-related quality of life, measured in either ‘utilities’ or ‘disability weights’ is an essential 
component of cost-effectiveness analysis and burden of disease studies. Decision-analytic models 
which underpin most of the comparative analysis of submissions to health technology assessment 
agencies such as NICE, CADTH and PBAC require robust data on utility-based quality of life for the 
calculation of quality adjusted life years (QALYs).
1-3
 Until now, the available data on utility-based 
quality of life for each AJCC melanoma stage has been limited to a few prospective studies with small 
numbers of participants. In the article that accompanies this editorial, Tromme et al
4
  present mean 
utilities and disability weights for both melanoma treatment and remission (i.e. follow-up) health 
states. The authors are to be commended for their robust calculation of precision estimates using 
statistical bootstrap methods that allow health economists and modellers to use upper and lower limits 
in sensitivity analyses. 
Two important points concerning the empiric measurement of health-related quality of life for 
melanoma patients need to be highlighted. The first is that the instruments or questionnaires used 
should be sensitive to the domains of quality of life that are likely to change as a result of the disease, 
the routine treatment or a targeted intervention. Tromme et al report that over half the melanoma 
patients in their study reported anxiety or depression, however this domain on the EQ-5D-5L 
instrument was somewhat insensitive to detecting this health state.
4
 Similar findings are reported in a 
review of existing quality of life instruments where little attention was given to psychosocial or 
emotional wellbeing, two of the issues most pertinent to melanoma patients.
5
 Given this, clinician 
researchers should question whether the EQ-5D-5L is an appropriate choice for future cost-
effectiveness studies. The Assessment of Quality Of Life eight dimensions (AQOL-8D) is an 
alternative utility-based instrument that may be more sensitive to changes in mental health, and 
therefore more useful for economic evaluations.
6
  
The second point relates to melanoma follow-up. Patients in follow-up, often referred to as melanoma 
survivors, constitute a large and growing proportion of the dermatology / oncology caseload.
7
 Best 
practice indicates that cost-effectiveness analyses should adopt a patient lifetime horizon, and this 
therefore involves longitudinal estimates of quality of life following treatment. Longitudinal 
assessment is needed to help us understand the factors that influence quality of life, and why for 
example patients with AJCC stage IV melanoma in remission, are reported to have a higher quality of 
life than patients with resected AJCC stage III disease.
4
 A detailed description is currently lacking of 
the activities that are undertaken during follow-up care for each melanoma stage, including the 
personnel who provide follow-up care. These factors combined with the frequency of follow-up visits 
and the use of diagnostic imaging can all impact on patients’ quality of life.   
Further research in these areas will lead to more accurate estimates of health-related quality of life 
over the longer term. Good quality data can better inform decisions about the allocation of resources 
for melanoma patients. 
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